Pharmaceuticals - , Colorado, United States
Machavert develops first in class small molecule RAL GTPase inhibitors that target KRAS mutant cancers growth and metastasis.
Outlook
Nginx
WordPress.org
Google Font API
Google Analytics
Mobile Friendly